Richard C. Bethell

7.0k total citations · 1 hit paper
83 papers, 5.1k citations indexed

About

Richard C. Bethell is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Richard C. Bethell has authored 83 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Epidemiology, 28 papers in Infectious Diseases and 28 papers in Molecular Biology. Recurrent topics in Richard C. Bethell's work include HIV/AIDS drug development and treatment (28 papers), Influenza Virus Research Studies (26 papers) and HIV Research and Treatment (18 papers). Richard C. Bethell is often cited by papers focused on HIV/AIDS drug development and treatment (28 papers), Influenza Virus Research Studies (26 papers) and HIV Research and Treatment (18 papers). Richard C. Bethell collaborates with scholars based in United Kingdom, Canada and United States. Richard C. Bethell's co-authors include Larisa V. Gubareva, Robert G. Webster, Charles R. Penn, Peter M. Colman, Joseph Varghese, David Ryan, J. M. Cameron, Graham Hart, Wen‐Yang Wu and Betty Jin and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Richard C. Bethell

80 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rational design of potent sialidase-based inhibitors of influenza virus replication

1993 1.5k citations Mark von Itzstein, Wen‐Yang Wu et al. Nature profile →

Peers

Countries citing papers authored by Richard C. Bethell

Since Specialization

Citations

This map shows the geographic impact of Richard C. Bethell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Bethell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Bethell more than expected).

Fields of papers citing papers by Richard C. Bethell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Bethell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Bethell. The network helps show where Richard C. Bethell may publish in the future.

Co-authorship network of co-authors of Richard C. Bethell

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Bethell. A scholar is included among the top collaborators of Richard C. Bethell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Bethell. Richard C. Bethell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 1852: Systemic delivery of ST317, a cell penetrating STING pathway sensitizer, results in strong anti-tumor activity 2023 ·Cancer Research ·Claus Olesen, (unknown), (unknown), (unknown), (unknown), Justin V. Joseph, (unknown), Magnus Strandh, (unknown), (unknown), (unknown), (unknown), Richard C. Bethell, Martin R. Jakobsen	1
2	Safety and efficacy of six months' open label extension post-RCT using the novel cathepsin K inhibitor MIV-711 in patients with knee osteoarthritis 2019 ·Osteoarthritis and Cartilage ·Philip G. Conaghan, (unknown), Sarah R. Kingsbury, Allan S. Brett, Gwenael Guillard, (unknown), (unknown), A Jay Holmgren, (unknown), (unknown), Niclas Sjögren, P. A. Graham, Åsa Jansson, (unknown), Richard C. Bethell, John Öhd	2
3	P0688 : Preclinical characterisation of MIV-802, a novel uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection 2015 ·Journal of Hepatology ·(unknown), Helen Kylefjord, (unknown), (unknown), (unknown), Genadiy Kalayanov, Lotta Vrang, Eike Hoberg, Claes M. Gustafsson, (unknown), Erik Lindström, Kristina Wikström, Paul Targett‐Adams, Pedro Pinho, Richard C. Bethell, Åsa Rosenquist	1
4	CD160 isoforms and regulation of CD4 and CD8 T-cell responses 2014 ·Journal of Translational Medicine ·Mohamed El‐Far, Charles Pellerin, Louise Pilote, Jean-François Fortin, Ivan A.D. Lessard, Yoav Peretz, Elizabeth Wardrop, Patrick Salois, Richard C. Bethell, Michael G. Cordingley, George Kukolj	20
5	Nucleotide competing reverse transcriptase inhibitors: Discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Clint A. James, Patrick DeRoy, Martin Duplessis, Paul Edwards, (unknown), (unknown), Louis Morency, Sébastien Morin, Bruno Simoneau, Martin Tremblay, Richard C. Bethell, Michael G. Cordingley, Jianmin Duan, Louie Lamorte, Alex Pelletier, Daniel Rajotte, Patrick Salois, Sonia Tremblay, Claudio F. Sturino	8
6	Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor 2011 ·Xenobiotica ·Jianmin Duan, Chan‐Loi Yong, Michel Garneau, Ma’an Amad, Gordon T. Bolger, (unknown), (unknown), (unknown), Martin Jutras, (unknown), Peter W. White, Montse Llinàs‐Brunet, Richard C. Bethell, Michael G. Cordingley	13
7	Short Communication: Phenotypic Protease Inhibitor Resistance and Cross-Resistance in the Clinic from 2006 to 2008 and Mutational Prevalences in HIV from Patients with Discordant Tipranavir and Darunavir Susceptibility Phenotypes 2011 ·AIDS Research and Human Retroviruses ·Richard C. Bethell, Joseph Schérer, Myriam Witvrouw, Agnès Paquet, Eoin Coakley, David B. Hall	7
8	Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication 2009 ·Virology ·Frédéric H. Vaillancourt, Louise Pilote, Mireille Cartier, Julie Lippens, Michel Liuzzi, Richard C. Bethell, Michael G. Cordingley, George Kukolj	125
9	Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients 2006 ·AIDS ·Pedro Cahn, Isabel Cassetti, Robin Wood, Praphan Phanuphak, (unknown), Richard C. Bethell, J. Sawyer	33
10	Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase 2003 ·Journal of Biological Chemistry ·Meitian Wang, Kenneth Ng, M.M. Cherney, Laval Chan, Constantin G. Yannopoulos, Jean Bédard, (unknown), Nghe Nguyen‐Ba, Moulay Hicham Alaoui-Ismaili, Richard C. Bethell, Michael N.G. James	159
11	Genetic Analysis Reveals That Both Haemagglutinin and Neuraminidase Determine the Sensitivity of Naturally Occurring Avian Influenza Viruses to Zanamivir in Vitro 1999 ·Virology ·Susan J. Baigent, Richard C. Bethell, John W. McCauley	31
12	Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase 1999 ·Bioorganic & Medicinal Chemistry Letters ·Paul S. Jones, Paul W. Smith, George W. Hardy, Peter D. Howes, Richard J. Upton, Richard C. Bethell	8
13	In Vitro Selection and Characterisation of Influenza B/Beijing/1/87 Isolates with Altered Susceptibility to Zanamivir 1999 ·Virology ·Jacqueline M. Barnett, (unknown), (unknown), (unknown), Andrew Lewis, Margaret Tisdale, Richard C. Bethell	63
14	Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase 1999 ·Bioorganic & Medicinal Chemistry Letters ·Paul W. Smith, Naimisha Trivedi, Peter D. Howes, Steven L. Sollis, (unknown), Richard C. Bethell, Sean M. Lynn	13
15	Preclinical Development of Low Toxicity Drugs 1998 ·Drug Safety ·(unknown), Richard C. Bethell, (unknown)	14
16	Characterization of Influenza A/HongKong/156/97 (H5N1) Virus in a Mouse Model and Protective Effect of Zanamivir on H5N1 Infection in Mice 1998 ·The Journal of Infectious Diseases ·Larisa V. Gubareva, Jonathan A. McCullers, Richard C. Bethell, Robert G. Webster	121
17	Mutations Affecting the Sensitivity of the Influenza Virus Neuraminidase to 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic Acid 1997 ·Virology ·Hideo Goto, Richard C. Bethell, Yoshihiro Kawaoka	24
18	The intracellular phosphorylation of (−)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ 1995 ·Biochemical Pharmacology ·Norman M. Gray, (unknown), Charles R. Penn, J. M. Cameron, Richard C. Bethell	65
19	Discovery and Analysis of a Series of C2-Symmetric HIV-1 Proteinase Inhibitors Derived from Penicillin 1994 ·Analytical Biochemistry ·Norman M. Gray, (unknown), N. Cammack, Kevin N. Cobley, Duncan S. Holmes, David C. Humber, David Orr, Charles R. Penn, Richard Pötter, Shalom Madar, Gordon G. Weingarten, Richard C. Bethell	0
20	Rational design of potent sialidase-based inhibitors of influenza virus replication breakdown → 1993 ·Nature ·Mark von Itzstein, Wen‐Yang Wu, Gaik B. Kok, Michael S. Pegg, Jeffrey C. Dyason, Betty Jin, (unknown), Mark L. Smythe, (unknown), Stuart W. Oliver, Peter M. Colman, Joseph Varghese, David Ryan, (unknown), Richard C. Bethell, (unknown), J. M. Cameron, Charles R. Penn	1465

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact